345 related articles for article (PubMed ID: 33075344)
1. Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality.
Costa D; Simbrunner B; Jachs M; Hartl L; Bauer D; Paternostro R; Schwabl P; Scheiner B; Stättermayer AF; Pinter M; Trauner M; Mandorfer M; Reiberger T
J Hepatol; 2021 Apr; 74(4):819-828. PubMed ID: 33075344
[TBL] [Abstract][Full Text] [Related]
2. Dysregulated biomarkers of innate and adaptive immunity predict infections and disease progression in cirrhosis.
Simbrunner B; Hartl L; Jachs M; Bauer DJM; Scheiner B; Hofer BS; Stättermayer AF; Marculescu R; Trauner M; Mandorfer M; Reiberger T
JHEP Rep; 2023 May; 5(5):100712. PubMed ID: 37035457
[TBL] [Abstract][Full Text] [Related]
3. Lower free triiodothyronine (fT3) levels in cirrhosis are linked to systemic inflammation, higher risk of acute-on-chronic liver failure, and mortality.
Hartl L; Simbrunner B; Jachs M; Wolf P; Bauer DJM; Scheiner B; Balcar L; Semmler G; Schwarz M; Marculescu R; Dannenberg V; Trauner M; Mandorfer M; Reiberger T
JHEP Rep; 2024 Jan; 6(1):100954. PubMed ID: 38125301
[TBL] [Abstract][Full Text] [Related]
4. An impaired pituitary-adrenal signalling axis in stable cirrhosis is linked to worse prognosis.
Hartl L; Simbrunner B; Jachs M; Wolf P; Bauer DJM; Scheiner B; Balcar L; Semmler G; Schwarz M; Marculescu R; Trauner M; Mandorfer M; Reiberger T
JHEP Rep; 2023 Aug; 5(8):100789. PubMed ID: 37484210
[TBL] [Abstract][Full Text] [Related]
5. Von Willebrand factor for outcome prediction within different clinical stages of advanced chronic liver disease.
Dominik N; Scheiner B; Zanetto A; Balcar L; Semmler G; Campello E; Schwarz M; Paternostro R; Simbrunner B; Hofer BS; Stättermayer AF; Pinter M; Trauner M; Quehenberger P; Simioni P; Reiberger T; Mandorfer M
Aliment Pharmacol Ther; 2024 Jun; 59(11):1376-1386. PubMed ID: 38482706
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of substantially elevated von Willebrand factor antigen levels in patients with advanced chronic liver disease.
Pomej K; Scheiner B; Balcar L; Nussbaumer RJ; Weinzierl J; Paternostro R; Simbrunner B; Bauer D; Pereyra D; Starlinger P; Stättermayer AF; Pinter M; Trauner M; Quehenberger P; Reiberger T; Mandorfer M
Dig Liver Dis; 2022 Oct; 54(10):1376-1384. PubMed ID: 35871985
[TBL] [Abstract][Full Text] [Related]
7. Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient.
Jachs M; Hartl L; Simbrunner B; Semmler G; Balcar L; Hofer BS; Schwarz M; Bauer D; Stättermayer AF; Pinter M; Trauner M; Reiberger T; Mandorfer M
J Hepatol; 2024 May; 80(5):744-752. PubMed ID: 38218352
[TBL] [Abstract][Full Text] [Related]
8. Red cell distribution width/platelet ratio estimates the 3-year risk of decompensation in Metabolic Dysfunction-Associated Steatotic Liver Disease-induced cirrhosis.
Dallio M; Romeo M; Vaia P; Auletta S; Mammone S; Cipullo M; Sapio L; Ragone A; Niosi M; Naviglio S; Federico A
World J Gastroenterol; 2024 Feb; 30(7):685-704. PubMed ID: 38515952
[TBL] [Abstract][Full Text] [Related]
9. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.
Ripoll C; Groszmann R; Garcia-Tsao G; Grace N; Burroughs A; Planas R; Escorsell A; Garcia-Pagan JC; Makuch R; Patch D; Matloff DS; Bosch J;
Gastroenterology; 2007 Aug; 133(2):481-8. PubMed ID: 17681169
[TBL] [Abstract][Full Text] [Related]
10. Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis.
Turco L; Garcia-Tsao G; Magnani I; Bianchini M; Costetti M; Caporali C; Colopi S; Simonini E; De Maria N; Banchelli F; Rossi R; Villa E; Schepis F
J Hepatol; 2018 May; 68(5):949-958. PubMed ID: 29331339
[TBL] [Abstract][Full Text] [Related]
11. Alcohol Abstinence Improves Prognosis Across All Stages of Portal Hypertension in Alcohol-Related Cirrhosis.
Hofer BS; Simbrunner B; Hartl L; Jachs M; Bauer DJM; Balcar L; Paternostro R; Schwabl P; Semmler G; Scheiner B; Staettermayer AF; Trauner M; Mandorfer M; Reiberger T
Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2308-2317.e7. PubMed ID: 36481475
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension.
Paternostro R; Bardach C; Hofer BS; Scheiner B; Schwabl P; Asenbaum U; Ba-Ssalamah A; Scharitzer M; Bucscis T; Simbrunner B; Bauer D; Trauner M; Mandorfer M; Reiberger T; Lampichler K
Liver Int; 2021 Apr; 41(4):799-809. PubMed ID: 33290614
[TBL] [Abstract][Full Text] [Related]
13. Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD.
Scheiner B; Balcar L; Nussbaumer RJ; Weinzierl J; Paternostro R; Simbrunner B; Hartl L; Jachs M; Bauer D; Stättermayer AF; Semmler G; Pinter M; Ay C; Quehenberger P; Trauner M; Reiberger T; Lisman T; Mandorfer M
J Hepatol; 2022 May; 76(5):1090-1099. PubMed ID: 35066090
[TBL] [Abstract][Full Text] [Related]
14. Gadoxetic acid-enhanced MRI-derived functional liver imaging score (FLIS) and spleen diameter predict outcomes in ACLD.
Bastati N; Beer L; Ba-Ssalamah A; Poetter-Lang S; Ambros R; Kristic A; Lauber D; Pomej K; Binter T; Simbrunner B; Semmler G; Balcar L; Bican Y; Hodge JC; Wrba T; Trauner M; Reiberger T; Mandorfer M
J Hepatol; 2022 Oct; 77(4):1005-1013. PubMed ID: 35525337
[TBL] [Abstract][Full Text] [Related]
15. Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease.
Balcar L; Krawanja J; Scheiner B; Paternostro R; Simbrunner B; Semmler G; Jachs M; Hartl L; Stättermayer AF; Schwabl P; Pinter M; Szekeres T; Trauner M; Reiberger T; Mandorfer M
JHEP Rep; 2023 Apr; 5(4):100682. PubMed ID: 36873421
[TBL] [Abstract][Full Text] [Related]
16. Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver disease.
Simbrunner B; Stadlmann A; Schwabl P; Paternostro R; Bauer DJM; Bucsics T; Scheiner B; Lampichler K; Wöran K; Beer A; Eigenbauer E; Pinter M; Stättermayer AF; Marculescu R; Szekeres T; Trauner M; Mandorfer M; Reiberger T
Dig Liver Dis; 2021 Mar; 53(3):345-352. PubMed ID: 33032973
[TBL] [Abstract][Full Text] [Related]
17. Thromboelastometry in patients with advanced chronic liver disease stratified by severity of portal hypertension.
Raeven P; Baron-Stefaniak J; Simbrunner B; Stadlmann A; Schwabl P; Scheiner B; Schaden E; Eigenbauer E; Quehenberger P; Mandorfer M; Baron DM; Reiberger T
Hepatol Int; 2020 Dec; 14(6):1083-1092. PubMed ID: 33000389
[TBL] [Abstract][Full Text] [Related]
18. Bacterial translocation occurs early in cirrhosis and triggers a selective inflammatory response.
Simbrunner B; Caparrós E; Neuwirth T; Schwabl P; Königshofer P; Bauer D; Marculescu R; Trauner M; Scheiner B; Stary G; Mandorfer M; Reiberger T; Francés R
Hepatol Int; 2023 Aug; 17(4):1045-1056. PubMed ID: 36881247
[TBL] [Abstract][Full Text] [Related]
19. Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis.
Simbrunner B; Semmler G; Stadlmann A; Scheiner B; Schwabl P; Paternostro R; Bucsics T; Bauer D; Eigenbauer E; Pinter M; Stättermayer AF; Quehenberger P; Marculescu R; Trauner M; Mandorfer M; Reiberger T
Hepatol Int; 2020 Dec; 14(6):1093-1103. PubMed ID: 33289910
[TBL] [Abstract][Full Text] [Related]
20. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis.
Ferlitsch M; Reiberger T; Hoke M; Salzl P; Schwengerer B; Ulbrich G; Payer BA; Trauner M; Peck-Radosavljevic M; Ferlitsch A
Hepatology; 2012 Oct; 56(4):1439-47. PubMed ID: 22532296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
